Targeted therapies in cancer :: an update /
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Biomedical,
[2016]
|
| Schriftenreihe: | Cancer etiology, diagnosis, and treatments.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 1 online resource. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781634847704 1634847709 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn952337061 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 160201s2016 nyu ob 001 0 eng | ||
| 010 | |a 2020676217 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d N$T |d EBLCP |d YDX |d OCLCF |d AGLDB |d SNK |d DKU |d IGB |d D6H |d VTS |d G3B |d S8J |d S9I |d STF |d OCLCO |d OCL |d OCLCO |d OCLCQ |d OCLCA |d OCL |d OCLCA |d OCLCO |d OCLCL |d OCLCA |d OCLCL | ||
| 019 | |a 961201701 | ||
| 020 | |a 9781634847704 |q ebook | ||
| 020 | |a 1634847709 | ||
| 020 | |z 1634846680 | ||
| 020 | |z 9781634846684 | ||
| 035 | |a (OCoLC)952337061 |z (OCoLC)961201701 | ||
| 050 | 0 | 0 | |a RC271.C5 |
| 060 | 4 | |a QZ 267 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.99/4061 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Lacroix, Marc, |d 1963- |e author. |1 https://id.oclc.org/worldcat/entity/E39PBJdMgGjmy9gdw8xCyCFR8C |0 http://id.loc.gov/authorities/names/n2007185401 | |
| 245 | 1 | 0 | |a Targeted therapies in cancer : |b an update / |c Marc Lacroix. |
| 264 | 1 | |a New York : |b Nova Biomedical, |c [2016] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Cancer etiology, diagnosis and treatments | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Description based on print version record. | ||
| 505 | 0 | |a TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs) | |
| 505 | 8 | |a 2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor | |
| 505 | 8 | |a 17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®) | |
| 505 | 8 | |a Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®) | |
| 505 | 8 | |a Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®) | |
| 650 | 0 | |a Cancer |x Chemotherapy. |0 http://id.loc.gov/authorities/subjects/sh85019497 | |
| 650 | 0 | |a Precision medicine. | |
| 650 | 0 | |a Cancer |x Treatment. |0 http://id.loc.gov/authorities/subjects/sh85019547 | |
| 650 | 2 | |a Neoplasms |x drug therapy |0 https://id.nlm.nih.gov/mesh/D009369Q000188 | |
| 650 | 2 | |a Precision Medicine. | |
| 650 | 6 | |a Cancer |x Chimiothérapie. | |
| 650 | 6 | |a Médecine de précision. | |
| 650 | 6 | |a Cancer |x Traitement. | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 7 | |a Cancer |x Treatment |2 fast | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast | |
| 650 | 7 | |a Precision medicine |2 fast | |
| 758 | |i has work: |a Targeted therapies in cancer (Text) |1 https://id.oclc.org/worldcat/entity/E39PCH399fkp7xHPVx3Wrt6hBK |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Targeted therapies in cancer |d New York : Nova Biomedical, [2016] |z 9781634846684 |w (DLC) 2016932180 |
| 830 | 0 | |a Cancer etiology, diagnosis, and treatments. |0 http://id.loc.gov/authorities/names/n2009183163 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258722 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 12882109 | ||
| 938 | |a EBSCOhost |b EBSC |n 1258722 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4591497 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn952337061 |
|---|---|
| _version_ | 1816882352602742785 |
| adam_text | |
| any_adam_object | |
| author | Lacroix, Marc, 1963- |
| author_GND | http://id.loc.gov/authorities/names/n2007185401 |
| author_facet | Lacroix, Marc, 1963- |
| author_role | aut |
| author_sort | Lacroix, Marc, 1963- |
| author_variant | m l ml |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 |
| callnumber-search | RC271.C5 |
| callnumber-sort | RC 3271 C5 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs) 2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor 17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®) Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®) Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®) |
| ctrlnum | (OCoLC)952337061 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06069cam a2200769 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn952337061</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160201s2016 nyu ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2020676217</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">OCLCF</subfield><subfield code="d">AGLDB</subfield><subfield code="d">SNK</subfield><subfield code="d">DKU</subfield><subfield code="d">IGB</subfield><subfield code="d">D6H</subfield><subfield code="d">VTS</subfield><subfield code="d">G3B</subfield><subfield code="d">S8J</subfield><subfield code="d">S9I</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">961201701</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634847704</subfield><subfield code="q">ebook</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634847709</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1634846680</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781634846684</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)952337061</subfield><subfield code="z">(OCoLC)961201701</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RC271.C5</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QZ 267</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lacroix, Marc,</subfield><subfield code="d">1963-</subfield><subfield code="e">author.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJdMgGjmy9gdw8xCyCFR8C</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2007185401</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted therapies in cancer :</subfield><subfield code="b">an update /</subfield><subfield code="c">Marc Lacroix.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Biomedical,</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Cancer etiology, diagnosis and treatments</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®)</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85019497</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Precision medicine.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85019547</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009369Q000188</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Precision Medicine.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Chimiothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médecine de précision.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Precision medicine</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Targeted therapies in cancer (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCH399fkp7xHPVx3Wrt6hBK</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Targeted therapies in cancer</subfield><subfield code="d">New York : Nova Biomedical, [2016]</subfield><subfield code="z">9781634846684</subfield><subfield code="w">(DLC) 2016932180</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Cancer etiology, diagnosis, and treatments.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2009183163</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258722</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12882109</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1258722</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4591497</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn952337061 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:27:15Z |
| institution | BVB |
| isbn | 9781634847704 1634847709 |
| language | English |
| lccn | 2020676217 |
| oclc_num | 952337061 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Nova Biomedical, |
| record_format | marc |
| series | Cancer etiology, diagnosis, and treatments. |
| series2 | Cancer etiology, diagnosis and treatments |
| spelling | Lacroix, Marc, 1963- author. https://id.oclc.org/worldcat/entity/E39PBJdMgGjmy9gdw8xCyCFR8C http://id.loc.gov/authorities/names/n2007185401 Targeted therapies in cancer : an update / Marc Lacroix. New York : Nova Biomedical, [2016] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Cancer etiology, diagnosis and treatments Includes bibliographical references and index. Description based on print version record. TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs) 2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor 17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®) Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®) Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®) Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Precision medicine. Cancer Treatment. http://id.loc.gov/authorities/subjects/sh85019547 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Precision Medicine. Cancer Chimiothérapie. Médecine de précision. Cancer Traitement. HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Cancer Treatment fast Cancer Chemotherapy fast Precision medicine fast has work: Targeted therapies in cancer (Text) https://id.oclc.org/worldcat/entity/E39PCH399fkp7xHPVx3Wrt6hBK https://id.oclc.org/worldcat/ontology/hasWork Print version: Targeted therapies in cancer New York : Nova Biomedical, [2016] 9781634846684 (DLC) 2016932180 Cancer etiology, diagnosis, and treatments. http://id.loc.gov/authorities/names/n2009183163 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258722 Volltext |
| spellingShingle | Lacroix, Marc, 1963- Targeted therapies in cancer : an update / Cancer etiology, diagnosis, and treatments. TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs) 2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor 17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®) Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®) Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®) Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Precision medicine. Cancer Treatment. http://id.loc.gov/authorities/subjects/sh85019547 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Precision Medicine. Cancer Chimiothérapie. Médecine de précision. Cancer Traitement. HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Cancer Treatment fast Cancer Chemotherapy fast Precision medicine fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85019497 http://id.loc.gov/authorities/subjects/sh85019547 https://id.nlm.nih.gov/mesh/D009369Q000188 |
| title | Targeted therapies in cancer : an update / |
| title_auth | Targeted therapies in cancer : an update / |
| title_exact_search | Targeted therapies in cancer : an update / |
| title_full | Targeted therapies in cancer : an update / Marc Lacroix. |
| title_fullStr | Targeted therapies in cancer : an update / Marc Lacroix. |
| title_full_unstemmed | Targeted therapies in cancer : an update / Marc Lacroix. |
| title_short | Targeted therapies in cancer : |
| title_sort | targeted therapies in cancer an update |
| title_sub | an update / |
| topic | Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Precision medicine. Cancer Treatment. http://id.loc.gov/authorities/subjects/sh85019547 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Precision Medicine. Cancer Chimiothérapie. Médecine de précision. Cancer Traitement. HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Cancer Treatment fast Cancer Chemotherapy fast Precision medicine fast |
| topic_facet | Cancer Chemotherapy. Precision medicine. Cancer Treatment. Neoplasms drug therapy Precision Medicine. Cancer Chimiothérapie. Médecine de précision. Cancer Traitement. HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine Cancer Treatment Cancer Chemotherapy Precision medicine |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258722 |
| work_keys_str_mv | AT lacroixmarc targetedtherapiesincanceranupdate |